Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.61 |
| ▸ | CES1 | P23141 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8566777 | 0.84 | CES2 (0.61) | CES2CES1KMT2AHTTNPC1 | |
| SCHEMBL31270828 | 0.84 | CES2 (0.61) | CES2CES1KMT2AHTTNPC1 | |
| SCHEMBL2735675 | 0.82 | PDK2 (0.46) | CES2CES1KMT2AHTTL3MBTL1 | |
| SCHEMBL355779 | 0.82 | PDK2 (0.47) | CES2CES1KMT2ANPC1L3MBTL1 | |
| SCHEMBL15218738 | 0.82 | CES2 (0.53) | CES2CES1KMT2AHTTACKR3 | |
| SCHEMBL6710893 | 0.82 | CES2 (0.53) | CES2CES1KMT2AHTTACKR3 | |
| SCHEMBL21516873 | 0.81 | MAP2K1 (0.52) | CES2CES1KMT2AL3MBTL1 | |
| SCHEMBL646187 | 0.81 | DGAT1 (0.59) | CES2CES1KMT2ANPC1L3MBTL1 | |
| SCHEMBL356822 | 0.81 | KMT2A (0.42) | CES2CES1KMT2AL3MBTL1 | |
| SCHEMBL19454401 | 0.81 | KMT2A (0.42) | CES2CES1KMT2ANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2750238-B1 | NON-AQUEOUS ELECTROLYTE AND BATTERY | DAIKIN IND LTD (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-9627714-B2 | Non-aqueous electrolyte and battery | DAIKIN INDUSTRIES, LTD. (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9627714-B2 | Non-aqueous electrolyte and battery | DAIKIN INDUSTRIES, LTD. (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9509016-B2 | Battery and non-aqueous electrolyte | DAIKIN INDUSTRIES, LTD. (JP) | 2016-11-29 | — | — | US | disclosed |
| US-9509016-B2 | Battery and non-aqueous electrolyte | DAIKIN INDUSTRIES, LTD. (JP) | 2016-11-29 | — | — | US | disclosed |
| US-9455474-B2 | Electrolytic solution | DAIKIN INDUSTRIES, LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9455474-B2 | Electrolytic solution | DAIKIN INDUSTRIES, LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9397368-B2 | Non-aqueous electrolyte solution | DAIKIN INDUSTRIES, LTD. (JP) | 2016-07-19 | — | — | US | disclosed |
| US-9397368-B2 | Non-aqueous electrolyte solution | DAIKIN INDUSTRIES, LTD. (JP) | 2016-07-19 | — | — | US | disclosed |
| US-20150004501-A1 | NON-AQUEOUS ELECTROLYTE AND BATTERY | DAIKIN INDUSTRIES, LTD. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-20130224606-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION | DAIKIN INDUSTRIES, LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130224606-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION | DAIKIN INDUSTRIES, LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2010520-B1 | HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PROD INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2463283-A1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | Pfizer Products Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8119624-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | PFIZER INC | 2011-02-17 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039821-A1 | Fused Phenyl Amido Heterocyclic Compounds | GCK, GCKR, HK1 | CES2 1354/4885CES1 614/4885KMT2A 1755/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | CES2 1354/4885CES1 614/4885KMT2A 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.